Renibus Therapeutics Presents Interim Phase 2 Data: RBT-1 Improves Post-Operative Outcomes in Cardiac Surgery Patients During Oral Session at AHA Scientific Sessions 2022

Renibus Therapeutics Presents Interim Phase 2 Data: RBT-1 Improves [...]

Michael Jaramillo2022-11-07T12:12:44-08:00November 7, 2022|

Renibus Therapeutics Announces Participation in Multiple Upcoming Investor Conferences

Michael Jaramillo2022-10-15T15:56:08-07:00October 5, 2022|

Renibus Therapeutics Announces Positive Interim Data from RBT-1 Phase 2 Trial

Michael Jaramillo2022-10-15T15:56:48-07:00June 15, 2022|

Renibus Therapeutics Expands Leadership Team, Announces Appointments of New Chief Financial Officer and Chief Medical Officer

Michael Jaramillo2022-10-15T15:56:54-07:00June 2, 2022|

Renibus Therapeutics Strengthens IP Position with Additional US Patent

Michael Jaramillo2022-10-15T15:57:00-07:00April 13, 2022|

Renibus Therapeutics Announces Appointment of Frank Stonebanks as CEO and $35 Million Series A Funding

Michael Jaramillo2022-10-15T15:57:06-07:00February 15, 2022|

Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2021

Michael Jaramillo2022-10-15T15:57:11-07:00October 28, 2021|

Rénibus Therapeutics® Initiates Phase 2 Study of RBT-1 for Prevention of Acute Kidney Injury

Michael Jaramillo2022-10-15T15:57:16-07:00March 11, 2021|

Rénibus Therapeutics® to Present Phase 1b Data on RBT-1 at Acute Kidney Injury & Continuous Renal Replacement Therapy 2021 Conference

Michael Jaramillo2022-10-15T15:57:24-07:00February 25, 2021|

Rénibus Therapeutics® Announces Publication of Positive Results of RBT-3 Experimental Preclinical Studies in Scientific Journal Nephrology Dialysis Transplant

Michael Jaramillo2022-10-15T15:57:30-07:00February 16, 2021|